Former Interim President and Chief Executive Officer · Arbutus Biopharma Corp (ABUS)

Michael McElhaugh

A named executive officer of Arbutus Biopharma in every fiscal year CompBrief holds from FY2020 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$3,578,150

FY2024: $2,110,083

1st of 4 named executive officers at Arbutus Biopharma by FY2025 total.

4 named officers on file for Arbutus Biopharma, FY2025

See an example →

What this number hides

The filing gives the total. Arbutus Biopharma’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Arbutus Biopharma’s whole pay program stands against its peers

  • Arbutus Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABUS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 14, 2026 (DEF 14A).

Free

Get Michael McElhaugh’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Michael McElhaugh and every company like it: Velarion Intel, free for 3 days, no card →

Michael McElhaugh compensation by year

Arbutus Biopharma Summary Compensation Table · all 5 fiscal years held
In US dollars, as Arbutus Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2022FY2023FY2024FY2025
Salary$415,000$448,750$483,000$642,500$109,658
Bonus$0$0$0$0$0
Stock awards$0$0$242,730$297,120$582,330
Option awards$484,366$708,610$733,355$921,463$1,855,495
Non-equity incentive$178,450$147,200$144,900$231,750$0
Pension and deferred compensation$0$0$0$0$0
All other$9,975$10,675$16,500$17,250$1,030,667
Total$1,087,791$1,315,235$1,620,485$2,110,083$3,578,150

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 14, 2026, accession 0001140361-26-014623, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Arbutus Biopharma Corp filed document, accession 0001140361-26-014623. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2026.

$1.1M
$1.3M
$1.6M
$2.1M
$3.6M
FY20
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU123,800$404,826—
RSU55,800$182,466—
Option10,375—$4.33
Option88,251—$2.81
Option181,296—$2.90
Option391,954—$2.40

Per the Outstanding Equity Awards at Fiscal Year-End table in Arbutus Biopharma Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments Arbutus Biopharma discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$986,825——$986,825

Per the Potential Payments Upon Termination or Change in Control table in Arbutus Biopharma Corp's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

Arbutus Biopharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Michael McElhaugh · this pageFormer Interim President and Chief Executive Officer$3,578,150
Tuan NguyenChief Financial Officer$2,416,995
David HastingsFormer Chief Financial Officer$2,218,362
Lindsay AndroskiPresident and Chief Executive Officer$1,369,013

Board service

Arbutus Biopharma board · FY2023–FY2025

How this board is paid

Company policy: Arbutus Biopharma pays directors a $40,000 cash retainer. As stated in Arbutus Biopharma's FY2025 proxy.

Michael McElhaugh's compensation dossier, Arbutus Biopharma

You have read Michael McElhaugh's totals and holdings. The dossier adds each equity grant Arbutus Biopharma disclosed for Michael McElhaugh and Arbutus Biopharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Arbutus Biopharma compensation record

free company brief

This page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arbutus Biopharma's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order ABUS

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Michael McElhaugh's compensation dossier